Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rhabdomyolysis Caused by Gefitinib Overdose.

Internal medicine (Tokyo, Japan) - 15 May 2022

Obayashi Shohei, Tomomatsu Katsuyoshi, Urata Mika, Tanaka Jun, Niimi Kyoko, Hayama Naoki, Oguma Tsuyoshi, Asano Koichiro, Ito Yoko

Abstract excerpt

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are common therapeutic agents for EGFR mutation-positive advanced non-small-cell lung cancer. There has been no report of rhabdomyolysis caused by an overdose of EGFR-TKIs. We herein review the existing literature on the subject and report a rare case of rhabdomyolysis due to an overdose of gefitinib, an EGFR-TKI.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Rhabdomyolysis

Source

Open in PubMed Open full text

Identifiers

PMID: 34707044
DOI: 10.2169/internalmedicine.8168-21
PMCID: PMC9177374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Rhabdomyolysis Caused by Gefitinib Overdose.PMID 34707044Read ↗

Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.Semantic proximity Read ↗

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.Semantic proximity Read ↗

Severe rhabdomyolysis associated with etoposide-nedaplatin chemotherapy in a patient with small cell lung cancer：case report and review of literatureSemantic proximity Read ↗

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.Semantic proximity Read ↗

Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case.Semantic proximity Read ↗

Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.Semantic proximity Read ↗

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].Semantic proximity Read ↗

A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.